Patents by Inventor Alexander LAPERLE

Alexander LAPERLE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11987780
    Abstract: Described herein is functionalized glass allowing for robust attachment of extracellular matrix proteins (ECM) withstanding extended culturing periods. By first treating glass with a sulfur silane reagent, the treated glass can be activated via an amine-sulfur linker, after which ECM proteins are attached to the linker. The Inventors observed that this glass treatment combination (sulfur silane-linker-ECM) resisted degradation when compared to conventional surface coatings, such as poly-L-orthinine coated glass.
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: May 21, 2024
    Assignee: Cedars-Sinai Medical Center
    Inventors: Alexander Laperle, Clive Svendsen
  • Patent number: 11981918
    Abstract: Induced Pluripotent Stem Cell (Ipsc) technology enables the generation and study of living brain tissue relevant to Parkinson's disease (PD) ex vivo. Utilizing cell lines from PD patients presents a powerful discovery system that links cellular phenotypes observed in vitro with real clinical data. Differentiating patient-derived iPSCs towards a dopaminergic (DA) neural fate revealed that these cells exhibit molecular and functional properties of DA neurons in vitro that are observed to significantly degenerate in the substantia nigra of PD patients. Clinical symptoms that drive the generation of other relevant cell types may also yield novel PD-specific phenotypes in vitro that have the potential to lead to new therapeutic avenues for patients with PD.
    Type: Grant
    Filed: April 5, 2019
    Date of Patent: May 14, 2024
    Assignee: Cedars-Sinai Medical Center
    Inventors: Alexander Laperle, Samuel Sances, Nur Yucer, Clive N. Svendsen
  • Publication number: 20240076629
    Abstract: Described herein is the production neural progenitor cell lines (NPCs) derived from human induced pluripotent stem cells (iPSCs). These iPSC-derived NPCs engraft efficiently into the spinal cord of ALS animal models and provide neuroprotection to diseased motor neurons, similar to the fetal-derived cells used in clinical study. Clonal lines were generated with a single copy GDNF construct inserted in the AAVS1 safe landing site, including inducible expression of GDNF expression. These new iPSC-derived NPC lines are scalable to clinically relevant production volumes, uniformly produce GDNF, are safe, and represent a promising new combination therapy for neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS).
    Type: Application
    Filed: October 22, 2020
    Publication date: March 7, 2024
    Applicant: Cedars-Sinai Medical Center
    Inventors: Alexander LAPERLE, Aaron FULTON, Clive N. SVENDSEN
  • Publication number: 20240067933
    Abstract: Mechanical chopping has been successfully used to expand both fetal and iPSC-derived neural progenitor cells to scales suitable for early phase clinical trials. However, this method is time-consuming, labor-intensive, and challenging to implement at larger scales. Described herein are methods, apparatuses and systems for a novel in-line passaging technique that maintains the expansion rate and cellular identity of mechanical chopping but that is faster, scalable, and can be implemented in a fully sealed system.
    Type: Application
    Filed: October 22, 2020
    Publication date: February 29, 2024
    Applicant: Cedars-Sinai Medical Center
    Inventors: Alexander LAPERLE, Aaron FULTON, Clive N. SVENDSEN
  • Publication number: 20210130774
    Abstract: Described herein is a microphysiological system for models of disease. Specifically, induced pluripotent stem cells (iPSCs) and iPSC-derived cells, including those obtained from disease patients, are seeded onto microfluidic “chip” devices to study cellular development and disease pathogenesis. Herein, neurodegenerative disease modeling, including Parkinson's Disease (PD) is shown to reproduce key PD pathology in a vascularized human model that contains neurons relating to PD pathology. Such compositions and methods are used for research for PD biomarkers, patient screening for PD risk assessment, and therapeutic discovery and testing. A panel of biomarkers are generated through analysis of living PD-chips by neural activity, whole transcriptomic, proteomic, and metabolomic analysis, and functional enzyme tests of media and tissue.
    Type: Application
    Filed: April 5, 2019
    Publication date: May 6, 2021
    Applicant: Cedars-Sinai Medical Center
    Inventors: Samuel SANCES, Alexander LAPERLE, Nur YUCER, Clive N. SVENDSEN
  • Publication number: 20210033628
    Abstract: Induced Pluripotent Stem Cell (Ipsc) technology enables the generation and study of living brain tissue relevant to Parkinson's disease (PD) ex vivo. Utilizing cell lines from PD patients presents a powerful discovery system that links cellular phenotypes observed in vitro with real clinical data. Differentiating patient-derived iPSCs towards a dopaminergic (DA) neural fate revealed that these cells exhibit molecular and functional properties of DA neurons in vitro that are observed to significantly degenerate in the substantia nigra of PD patients. Clinical symptoms that drive the generation of other relevant cell types may also yield novel PD-specific phenotypes in vitro that have the potential to lead to new therapeutic avenues for patients with PD.
    Type: Application
    Filed: April 5, 2019
    Publication date: February 4, 2021
    Applicant: CEDARS-SINAI MEDICAL CENTER
    Inventors: Alexander Laperle, Samuel Sances, Nur Yucer, Clive N. Svendsen
  • Publication number: 20210023039
    Abstract: Induced Pluripotent Stem Cell (iPSC) technology enables the generation and study of living brain tissue relevant to Parkinson's disease (PD) ex vivo. Utilizing cell lines from PD patients presents a powerful discovery system that links cellular phenotypes observed in vitro with real clinical data. Differentiating patient derived iPSCs towards a dopaminergic (DA) neural fate revealed that these cells exhibit molecular and functional properties of DA neurons in vitro that are observed to significantly degenerate in the substantia nigra of PD patients. Clinical symptoms that drive the generation of other relevant cell types may also yield novel PD specific phenotypes in vitro that have the potential to lead to new therapeutic avenues for patients with PD.
    Type: Application
    Filed: April 5, 2019
    Publication date: January 28, 2021
    Applicant: CEDARS-SINAI MEDICAL CENTER
    Inventors: Alexander Laperle, Samuel Sances, Nur Yucer, Clive N. Svendsen
  • Publication number: 20210024886
    Abstract: Induced Pluripotent Stem Cell (Ipsc) technology enables the generation and study of living brain tissue relevant to Parkinson's disease (PD) ex vivo. Utilizing cell lines from PD patients presents a powerful discovery system that links cellular phenotypes observed in vitro with real clinical data. Differentiating patient-derived iPSCs towards a dopaminergic (DA) neural fate revealed that these cells exhibit molecular and functional properties of DA neurons in vitro that are observed to significantly degenerate in the substantia nigra of PD patients. Clinical symptoms that drive the generation of other relevant cell types may also yield novel PD-specific phenotypes in vitro that have the potential to lead to new therapeutic avenues for patients with PD.
    Type: Application
    Filed: April 5, 2019
    Publication date: January 28, 2021
    Applicant: CEDARS-SINAI MEDICAL CENTER
    Inventors: Alexander Laperle, Samuel Sances, Nur Yucer, Clive N. Svendsen
  • Publication number: 20200224140
    Abstract: Described herein is functionalized glass allowing for robust attachment of extracellular matrix proteins (ECM) withstanding extended culturing periods. By first treating glass with a sulfur silane reagent, the treated glass can be activated via an amine-sulfur linker, after which ECM proteins are attached to the linker. The Inventors observed that this glass treatment combination (sulfur silane-linker-ECM) resisted degradation when compared to conventional surface coatings, such as poly-L-orthinine coated glass.
    Type: Application
    Filed: July 13, 2018
    Publication date: July 16, 2020
    Applicant: CEDARS-SINAI MEDICAL CENTER
    Inventors: Alexander LAPERLE, Clive SVENDSEN